Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 663-665

  Moon, Seong Mi ^a   Park, Hye Yun ^a   Jeong, Byeong Ho ^a   Jeon, Kyeongman ^a   Lee, Soo Youn ^a   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; ITRACONAZOLE; RIFABUTIN; RIFAMPICIN; ANTIFUNGAL AGENT; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CHRONIC PULMONARY ASPERGILLOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIMIT OF QUANTITATION; LUNG ASPERGILLOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM XENOPEI; ANTAGONISTS AND INHIBITORS; BLOOD; COINFECTION; COMPLICATION; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDY;

AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTIFUNGAL AGENTS; COINFECTION; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN;

EID: 84920167199     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04075-14     Document Type: Article

References (28)

1. Schweer KE, Bangard C, Hekmat K, Cornely OA. 2014. Chronic pulmonary aspergillosis. Mycoses 57:257-270. http://dx.doi.org/10.1111 /myc.12152.
2. Godet C, Philippe B, Laurent F, Cadranel J. 2014. Chronic pulmonary aspergillosis: an update on diagnosis and treatment. Respiration 88:162-174. http://dx.doi.org/10.1159/000362674.
3. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327-360. http://dx.doi.org/10.1086/525258.
4. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, Davies SF, Dismukes WE, Hage CA, Marr KA, Mody CH, Perfect JR, Stevens DA. 2011. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96-128. http://dx.doi.org/10.1164/rccm .2008-740ST.
5. Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. 2013. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 56:559-570. http://dx.doi.org/10.1111/myc.12075.
6. Denning DW, Pleuvry A, Cole DC. 2011. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89:864-872. http://dx.doi.org/10.2471/BLT.11.089441.
7. Smith NL, Denning DW. 2011. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37:865-872. http://dx.doi.org/10.1183/09031936.00054810.
8. Hafeez I, Muers MF, Murphy SA, Evans EG, Barton RC, McWhinney P. 2000. Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis. Thorax 55:717-719. http: //dx.doi.org/10.1136/thorax.55.8.717.
9. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M. 2006. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology 11:809-813. http://dx.doi.org/10.1111/j.1440-1843.2006.00952.x.
10. Kunst H, Wickremasinghe M, Wells A, Wilson R. 2006. Nontubercu-lous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 28:352-357. http://dx.doi.org/10.1183/09031936.06 .00139005.
11. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, Hayakawa H, Chida K. 2012. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 106:724-729. http://dx.doi.org/10.1016/j .rmed.2012.01.014.
12. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh WJ. 2013.Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol 51:811-817. http://dx.doi.org/10.3109/13693786 .2013.806826.
13. Zoumot Z, Boutou AK, Gill SS, van Zeller M, Hansell DM, Wells AU, Wilson R, Loebinger MR. 2014. Mycobacterium avium complex infection in non-cystic fibrosis bronchiectasis. Respirology 19:714-722. http://dx .doi.org/10.1111/resp.12287.
14. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416. http://dx.doi.org/10.1164/rccm.200604-571ST.
15. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Daza R, Daley CL, Dekhuijzen PN, Domingo D, Drobniewski F, Esteban J, Fauville-Dufaux M, Folkvardsen DB, Gibbons N, Gomez-Mampaso E, Gonzalez R, Hoffmann H, Hsueh PR, Indra A, Jagielski T, Jamieson F, Jankovic M, Jong E, Keane J, Koh WJ, Lange B, Leao S, Macedo R, Mannsaker T, Marras TK, Maugein J, Milburn HJ, Mlinko T, Morcillo N, Morimoto K, Papaventsis D, Palenque E, Paez-Pena M, Piersimoni C, Polanova M, Rastogi N, Richter E, Ruiz-Serrano MJ, Silva A, da Silva MP, Simsek H, van Soolingen D, Szabo N, Thomson R, Tortola Fernandez T, Tortoli E, Totten SE, Tyrrell G, Vasankari T, Villar M, Walkiewicz R, Winthrop KL, Wagner D. 2013. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 42:1604-1613. http: //dx.doi.org/10.1183/09031936.00149212.
16. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, Shin SJ, Kwon OJ. 2012. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest 142:1482-1488. http://dx.doi.org/10.1378/chest.12-0494.
17. Baciewicz AM, Chrisman CR, Finch CK, Self TH. 2008. Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126-136. http://dx.doi.org/10.1097/MAJ.0b013e31814a586a.
18. Baciewicz AM, Chrisman CR, Finch CK, Self TH. 2013. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29:1-12. http://dx.doi.org/10.1185/03007995.2012.747952.
19. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, Stevens DA. 1992. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 14:165-174. http://dx.doi.org/10.1093/clinids/14.1 .165.
20. Drayton J, Dickinson G, Rinaldi MG. 1994. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 18:266. http://dx.doi.org/10.1093/clinids/18.2.266.
21. Blomley M, Teare EL, de Belder A, Thway Y, Weston M. 1990. Itraconazole and anti-tuberculosis drugs. Lancet 336:1255.
22. Jaruratanasirikul S, Sriwiriyajan S. 1998. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 54:155-158. http://dx.doi.org/10.1007 /s002280050437.
23. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. 2003. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care. Med 167:603-662. http://dx.doi.org/10.1164/rccm.167.4.603.
24. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24-34. http://dx.doi.org/10.1128/AAC.00705-08.
25. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. 2004. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 43:725-732. http://dx.doi.org/10 .2165/00003088-200443110-00003.
26. Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. 2007. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 51:3455-3456. http://dx.doi.org/10.1128/AAC.00579-07.
27. Hohmann C, Kang EM, Jancel T. 2010. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations. Clin Infect Dis 50:939-940. http://dx.doi.org/10.1086/650740.
28. Krishna G, Parsons A, Kantesaria B, Mant T. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 23:545-552. http://dx .doi.org/10.1185/030079906X167507.